We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Clopidogrel Validated LC/MS Non-Proprietary Bioanalytical Method Announced

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Clopidogrel Validated LC/MS Non-Proprietary Bioanalytical Method Announced"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Advion BioServices announces the addition of clopidogrel, plus its active metabolite and its inactive carboxylic acid metabolite, to its list of validated LC/MS methods. The addition was made this month due to market demand for this bioanalytical method which few CROs offer.

Clopidogrel, commonly known as Plavix, is used to prevent blood clots that can lead to heart attacks and strokes. According to the Mayo Clinic, heart disease is the number one killer of men and women worldwide, and the primary form of treatment is a prescribed oral medicine such as clopidogrel. When a drug is commonly prescribed and often co-administered, it is important for pharmaceutical companies and doctors to understand how the drugs will interact with other classes of drugs by conducting crossover comparison studies.

This is especially important for drugs such as clopidogrel, where the active form of the drug is generated by cytochrome P450-mediated biotransformation. Advion is one of a few contract research organizations in the world offering bioanalytical assays specific for clopidogrel to support these studies.